Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more
Programmatic Asset
PROVEN INTELLIGENCE IN RNA PAYLOAD CHARACTERIZATION.
Programmatic Asset
Plasmid DNA Quality Control for RNA-LNP Therapeutic Manufacturing
CELL & GENE | RNA | BIOLOGICS
Executive Summary
The quality of plasmid DNA (pDNA) used as a template for in vitro transcription (IVT) is a foundational quality attribute for RNA-based lipid nanoparticle (LNP) therapies. Inconsistent or impure pDNA directly impacts the integrity of the resulting RNA payload, introducing variability that affects downstream formulation, biological activity, and safety profiles. This overview details the key QC metrics for pDNA, ensuring a robust and reproducible manufacturing process for next-generation therapies intended for multi-jurisdictional IND and IMPD submissions.
Frequently Asked Questions
Q: What are the primary plasmid DNA isoforms that impact RNA production for LNP therapy formulations?
The primary pDNA isoform is the supercoiled circular form, which is the most efficient template for in vitro transcription. Other isoforms, such as open-circular or linear DNA, are less efficient and can lead to truncated RNA transcripts. Our analytical services quantify the percentage of supercoiled pDNA to ensure optimal template quality for GxP-compliant RNA manufacturing.
Q: How do you ensure plasmid identity and integrity for IND-enabling programs?
We confirm plasmid identity using comprehensive sequence verification, typically via Next-Generation Sequencing (NGS), to guarantee the template matches the intended design. Integrity is assessed through methods that detect degradation or unwanted modifications. This rigorous characterization is a core component of the data package required for successful regulatory submissions under ICH guidelines.
Q: Why is controlling for endotoxin levels in plasmid DNA preparations important for RNA therapeutics?
Endotoxins are potent pyrogens that can elicit strong inflammatory and immune responses in vivo. For RNA-LNP therapies, which already have inherent immunogenic potential, minimizing endotoxin contamination from the initial pDNA template is a foundational step to de-risk the safety profile of the final therapeutic product.
The efficacy of an RNA therapeutic delivered via lipid nanoparticles is contingent on the fidelity of its RNA payload. This fidelity begins with the plasmid DNA template used in its synthesis. A well-characterized, high-purity pDNA template is the prerequisite for producing functional, full-length RNA, which in turn supports predictable biological outcomes.
The principle that formulation components dictate in vivo performance is well-established. Research into complex biologics has shown how delivery vehicles can alter vector tropism and efficiency (PMID: 19638960). Extrapolating this concept to RNA-LNP systems, any variability in the RNA payload itself introduces a confounding factor that complicates the interpretation of formulation-dependent effects. Stringent pDNA quality control eliminates this variable at the source.
Core pDNA Quality Attributes for IVT
A comprehensive analytical strategy for pDNA qualification focuses on four key areas. These metrics ensure that the input material for IVT is consistent, pure, and safe, supporting an 18-24 month timeline to IND.
-
Purity and Isoform Distribution: The biologically active, supercoiled isoform is the desired template for transcription. The presence of open-circular or linear isoforms can reduce transcription efficiency and yield truncated RNA products. We employ analytical techniques to quantify the relative distribution of these forms.
-
Identity Verification: The complete sequence of the plasmid must be confirmed to ensure it contains the correct template sequence, promoter, and terminator regions without unintended mutations.
-
Integrity: The pDNA must be free from significant degradation or chemical modifications that could impair the transcription process.
-
Safety and Residuals: Preparations must be analyzed for process-related impurities that could impact downstream processes or patient safety. Key residuals include endotoxins, host cell DNA, and host cell proteins (HCPs).
High-throughput in vivo screening platforms, which use barcoded mRNA to accelerate the identification of lead LNP candidates, depend on exceptionally consistent input materials to generate reliable data (PMID: 31678653). This level of consistency is only achievable when the pDNA template quality is rigorously controlled, ensuring that observed differences in performance are attributable to the LNP formulation, not the RNA payload.
Our >100,000 sq ft of specialized laboratory space provides the capacity for these detailed analytical programs. This infrastructure, combined with a team whose track record includes a 100% successful IND rate since 2019, provides the foundation for robust CMC data packages. Franklin Biolabs was formally launched in 2024, and this success rate reflects the deep history of our founding scientific leadership and core principal scientists.
For sponsors targeting global clinical programs, this analytical rigor supports harmonized submissions to multiple regulatory bodies, aligning with ICH guidelines. By establishing a well-characterized pDNA process, programs are better positioned for scalable and reproducible manufacturing.
This analytical framework is a component of our broader services. For more information on our comprehensive capabilities, please see our main Vector | CMC | Analytics Services page.
Featured Video: Franklin BioLab Facility Tour
This site tour showcases Franklin Biolabs’ preclinical and bioanalytical facilities, spanning >100k sq ft of animal housing and specialized laboratory space.
This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.